Tumor cells metastasize to distant organs through genetic and epigenetic alterations, including changes in microRNA (miR) expression. Here we find miR-22 triggers epithelial-mesenchymal transition (EMT), enhances invasiveness and promotes metastasis in mouse xenografts. In a conditional mammary gland-specific transgenic (TG) mouse model, we show that miR-22 enhances mammary gland sidebranching, expands the stem cell compartment, and promotes tumor development. Critically, miR-22 promotes aggressive metastatic disease in MMTVmiR-22 TG mice, as well as compound MMTV-neu or -PyVT-miR-22 TG mice. We demonstrate that miR-22 exerts its metastatic potential by silencing antimetastatic miR-200 through direct targeting of the TET (Ten eleven translocation) family of methylcytosine dioxygenases, thereby inhibiting demethylation of the mir-200 promoter. Finally, we show that miR-22 overexpression correlates with poor clinical outcomes and silencing of the TET-miR-200 axis in patients. Taken together, our findings implicate miR-22 as a crucial epigenetic modifier and promoter of EMT and breast cancer stemness toward metastasis.
SUMMARY
Tumor cells metastasize to distant organs through genetic and epigenetic alterations, including changes in microRNA (miR) expression. Here we find miR-22 triggers epithelial-mesenchymal transition (EMT), enhances invasiveness and promotes metastasis in mouse xenografts. In a conditional mammary gland-specific transgenic (TG) mouse model, we show that miR-22 enhances mammary gland sidebranching, expands the stem cell compartment, and promotes tumor development. Critically, miR-22 promotes aggressive metastatic disease in MMTVmiR-22 TG mice, as well as compound MMTV-neu or -PyVT-miR-22 TG mice. We demonstrate that miR-22 exerts its metastatic potential by silencing antimetastatic miR-200 through direct targeting of the TET (Ten eleven translocation) family of methylcytosine dioxygenases, thereby inhibiting demethylation of the mir-200 promoter. Finally, we show that miR-22 overexpression correlates with poor clinical outcomes and silencing of the TET-miR-200 axis in patients. Taken together, our findings implicate miR-22 as a crucial epigenetic modifier and promoter of EMT and breast cancer stemness toward metastasis.
INTRODUCTION
Metastasis remains one of most complex and challenging problems of contemporary oncology. During metastatic dissemination, a cancer cell from a primary tumor executes a multistep process: intravasation, survival in the circulation, extravasation, micrometastases, and colonization (Fidler, 2003) . Recent studies have demonstrated that as tumors progress, genetic and epigenetic mechanisms may result in the emergence of a self-renewing metastatic cancer stem cell (CSC), also referred to as cancer initiating cell (CIC) (Ito et al., 2009; Visvader and Lindeman, 2008) . This metastatic CSC eventually enters the blood stream and seeds a secondary tumor in a distinct organ. CSCs/CICs are thought to exist in primary tumors from the very early stages of tumorigenesis and may be the oncogenic derivatives of normal-tissue stem or progenitor cells.
CSCs may also arise as a consequence of the epithelialmesenchymal transition (EMT), a developmental program that is instrumental to the acquisition of stemness by nontransformed and tumor cells (Chaffer and Weinberg, 2011; Gupta and Massagué , 2006) . Although much progress has been garnered in elucidating the molecular pathways that trigger EMT and metastasis, a number of key mechanistic gaps remain to be explained, suggesting that critical players in the process have yet to be identified.
MicroRNAs (miRNAs) are small noncoding RNAs that lead to silencing of their cognate target genes by either degrading mRNA molecules or inhibiting their translation (Bartel, 2004) . Indeed, miRNAs have been implicated in the regulation of a variety of cellular processes, including stemness and metastasis, implying that they can function either as oncogenes or tumor suppressors (Calin et al., 2005; He et al., 2005; Ma et al., 2007) . For instance, the miR-200 family members (miR-200s) are known as tumor suppressive miRNAs that regulate the EMT and control stemness by directly targeting transcriptional repressor Zeb1/2 (zinc finger E-box-binding homeobox 1/2) and polycomb repressor complex proteins, such as Bmi1 (B lymphoma Mo-MLV insertion region 1 homolog) and Suz12 (suppressor of zeste 12 homolog) (Iliopoulos et al., 2010; Shimono et al., 2009 ). Interestingly, miR-200s are downregulated in different types of cancer (Adam et al., 2009; Bendoraite et al., 2010; Olson et al., 2009) , and they are specifically downregulated in breast CSCs in comparison with nontumorigenic cancer cells (Shimono et al., 2009) .
The selective deregulation of miRNA gene expression may be due to deletion, amplification, or mutations targeting the miRNAs themselves, as well as deregulation of transcription factors and epigenetic regulators targeting the genes encoding them (Breving and Esquela-Kerscher, 2010; Calin et al., 2005) . In particular, although promoter hypermethylation and associated inactivation of tumor suppressor genes is an established molecular hallmark of human cancer (Esteller, 2008; Jones and Baylin, 2007) , this epigenetic lesion has recently been extended to the DNA methylation-mediated silencing of miRNAs (Lujambio et al., 2007; Saito et al., 2006; Toyota et al., 2008) . DNA methylation can be heritably maintained across cell division, but can also be reversibly/ dynamically altered to establish new epigenetic programs.
The recent discovery of members of the TET (Ten eleven translocation) family that can specifically modify DNA by hydroxylating 5-methylcytosine (5mC) may explain how cells can erase existing methylation marks (Ito et al., 2010; Ko et al., 2010; Tahiliani et al., 2009) . Within the TET family of proteins, TET1, TET2, and TET3 have been shown to convert 5mC to 5-hydroxymethylcytosine (5hmC), whereas TET2-inactivating deletion and mutations have been frequently observed in hematopoietic malignancies (Ko et al., 2010; Tahiliani et al., 2009) . Notably, the level of 5hmC, so tightly associated with TET gene expression, is increased in differentiated cells and is profoundly reduced in many types of tumors, identifying 5hmC as a biomarker associated with tumor development (Haffner et al., 2011; Yang et al., 2013) .
Here, we show that miR-22 triggers enhanced mammary gland hyperplasia as well as a marked expansion of the mammary stem cell compartment, hence triggering tumor initiation. Importantly, we demonstrate that miR-22 promotes the metastatic process and EMT through its ability to repress the expression of miR-200s as well as 5hmC by directly targeting members of the TET family.
RESULTS

miR-22 Promotes EMT and Tumor Invasion and Metastasis
To investigate the potential oncogenic effects of miR-22 expression, we first transduced a retroviral vector encoding the human mir-22 gene into immortalized human breast epithelial cells, HMEC and MCF-10A, and unexpectedly found that ectopic expression of miR-22 results in an increased cell motility in an in vitro assay ( Figure S1A , available online, and data not shown). A dramatic morphological change was also observed in miR-22-overexpressing cells, in which the typical cobblestone-like appearance of normal epithelium was replaced by a spindlelike, fibroblastic morphology ( Figure S1B ). In agreement with these observations, we found that miR-22-overexpressing cells displayed a silenced expression of the key epithelial marker E-cadherin, and the upregulations of the mesenchymal markers N-cadherin, vimentin, and fibronectin ( Figures 1A, 1B and S1C). The EMT is known to be a central mechanism responsible for invasiveness and metastasis of breast cancer and is also associated with normal and malignant mammary stem cell function (Gupta and Massagué , 2006) . Therefore we speculated that miR-22 could also induce stemness. Noticeably, miR-22 expression increased the ability of MCF-10A cells to develop into mammosphere structures, suggesting that miR-22 triggers EMT and stemness ( Figures 1C, S1D , and S1E).
To determine whether miR-22 could induce similar effects in vivo, we next established a xenograft model using the nonmetastatic breast cancer cell line MCF-7. We used a miR-22/GFPexpressing retroviral vector to transduce MCF-7 cells and implanted them into cleared mammary fat pads of Nu/Nu immunodeficient mice (Figures S1F and S1G) . Within 3 weeks of injection, recipient mice developed macroscopic GFP + tumors with expansive and infiltrative growth patterns; by 12 weeks, in two of six cases massive lymphatic invasions were also observed in the adjacent normal breast tissues ( Figure 1D ). In comparison, at the same time point, MCF-7 control tumors were strictly noninvasive. The distribution, but not the total number of Ki67 + (proliferating) cells in miR-22-overexpressing tumors, was also distinct from that seen in the control tumors: in the former, large necrotic centers were apparent and Ki67 + cells were enriched in the highly vascularized invasive regions, whereas in the latter the vascularization was poor and the Ki67 + cells were evenly distributed ( Figures 1E and S1F) . Furthermore, the vessels associated with the invasive regions of miR-22-overexpressing tumors were observed not only in the stroma (peritumoral), but also within the epithelial tumor masses (intratumoral) ( Figures 1E and 1F ).
To determine whether miR-22-overexpressing MCF-7 cells could metastasize to distant sites, we undertook a detailed pathological analysis of the major organs of our implanted recipients. Strikingly, six out of six mice that received the orthotopic implantation of miR-22-overexpressing cells displayed numerous lung metastases that were readily detectable by both GFP fluorescence and histological analysis ( Figure 1G ). These clusters of cells were stained positive for Ki67 and estrogen receptor a (ERa), and negative for thyroid transcription factor 1 (TTF1; a marker of primary lung adenocarcinoma), further confirming their origin ( Figure 1H ). In contrast, no metastases were found in control animals ( Figure 1I ). Taken together, our data suggest that miR-22 can contribute to cell proliferation, invasion, and angiogenesis, and, importantly, can impart metastatic properties on otherwise nonmetastatic cells.
miR-22 Increases Mammary Stem Population and Promotes Tumorigenesis and Metastasis In Vivo In Transgenic Mice
Although these cell line studies were highly suggestive, we attempted to confirm and expand on our findings using a conditional transgenic mouse model. To this end, we engineered mice that harbored within their Collagen A1 locus the CAGGS promoter and the mir-22 genomic sequence separated by a LoxP flanked transcriptional STOP cassette (hereafter referred to as miR-22 F/+ ) (Figures 2A and 2B ). By crossing these mice with mice that express the Cre recombinase under the control of the mouse mammary tumor virus promoter (MMTV-Cre), we could induce targeted expression of miR-22 in the mammary glands. Real-time quantitative PCR and northern blot analyses revealed that miR-22 expression was increased 2-to 3-fold in miR-22
;MMTV-Cre mice compared to littermate controls ( Figure 2C ).
Noticeably, in agreement with our observation in cell line studies, epithelial cell migration and western blot analyses in breast epithelium obtained from miR-22
;MMTV-Cre and control mice revealed a marked increase in EMT features in cells from the transgenic animals at young age (Figures S1H and S1I) . Strikingly, by 7 weeks of age, miR-22 transgenic mice demonstrated an increased ductal side-branching (p < 0.001, Figure 2D ) and higher numbers of mammary stem cells (MSCs; defined as CD24 Figure 2E ), and cells from these mice displayed an increased ability to form mammospheres-3D structures in culture (p = 0.019, Figure S1J ). (H and I) H&E-, Ki67-, ERa-, and TTF1-stained sections of lungs isolated from mice that at 12 weeks after transplantation received orthotopic injection of MCF-7 cells expressing miR-22 (H). Scale bars, 50 mm. The number of lung micrometastases (micromets) per section in individual mice was also quantified (I). The data are represented as mean ± SD (n = 6). See Figures S1A-S1G.
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In agreement with these findings, it has been previously reported that miR-22 is highly expressed in mouse mammary progenitor cells (Ibarra et al., 2007) . Importantly, limiting dilution transplantation experiments with CD24 high CD49f high MSCs revealed that the increase in lobuloalveolar structures in miR-22 transgenic mice directly relates to MSCs, but not to aberrant hormonal signaling during the oestrus cycle (Figures 2F and 2G) .
Next, we performed a long-term evaluation of spontaneous mammary tumorigenesis and metastasis in vivo in miR-22 transgenic mice. Remarkably, miR-22 overexpression in mice resulted in a progressive decrease in the disease-free survival rate at the age of 8 to 24 months (n = 11) (p = 0.0024, Figure 3A ). Diffuse alveolar and ductal hyperplasia, focal mammary ductal ectasia, impaction of thick materials, and, more importantly, focal ductal carcinomas were observed in virgin female miR-22
;MMTV-Cre mice (at approximately 60% incidence), whereas no hyperplasia nor tumor was observed in control mice ( Figure 3B ). Noticeably, miR-22
;MMTV-Cre mice displayed EMT-related breast tumor phenotypes ( Figure 3C ), and their primary tumors represented both luminal (cytokeratin-8-positive and cytokeratin-14-negative) and mixed luminal-basal (cytokeratin-8-positive and cytokeratin-14-positive) cell fates, although the intensities of positivity of cytokeratin 8 are partially weaker than those of normal mammary glands ( Figure S2A ). Most strikingly, postpregnant miR-22
;MMTV-Cre mice developed lung metastases at 8 to 10 months of age (at 100% incidence) mostly in the peri-bronchiolar lymphatic space (n = 3) ( Figures 3D and 3E ).
In addition, by utilizing a series of genetically engineered mouse models, we further explored whether miR-22 can promote breast cancer and metastasis in vivo. As MMTV-PyVT transgenic mice are known to develop multifocal mammary tumors that spontaneously metastasize to the lung (Guy et al., 1992a) , we first crossed these mice with our miR-22 As MMTV-PyVT animals are difficult to compare precisely due to their very early onset of lung metastases, we next generated and analyzed MMTV-neu;miR-22
;MMTV-Cre mice, taking advantage of the fact that MMTV-neu mice express unactivated neu (c-ErbB2) and show less aggressive mammary tumors and lung metastases (Guy et al., 1992b) . Remarkably, the development of primary mammary gland lesions as well as the incidence of lung metastases was significantly increased in MMTV-neu;miR-22 MSCs isolated from 7-week-old miR-22 F/+ ;MMTV-Cre mice and littermate controls were injected into the cleared fat-pad of 3-week-old FVB/NJ female mice and whole-mount analyses were then conducted at 6 weeks after injection (G). Representative images of mammary gland side-branches are shown on the left. The resulting data were also analyzed by Chi-square test (right). See Figures S1H-S1J.
EMT-related breast tumor phenotypes (Figures 3G and S2E) . Interestingly, a significant number of MMTV-neu;miR-22
;MMTV-Cre breast tumors were both cytokeratin-8-positive and cytokeratin-14-positive, whereas MMTV-neu control primary tumors were cytokeratin-8-positive and cytokeratin-14-negative, suggesting that miR-22 induces a significant luminal-to-basal cell fate change in breast tumor cells in the presence of neu oncogene insult ( Figure S2F ). Notably, MMTV-neu;miR-22
;MMTV-Cre breast tumors also presented a significant increase in the population of CD24 pos CD90 pos CSCs compared to MMTV-neu control tumors ( Figure S2G and Malanchi et al., 2012) . Finally, the penetrance of metastases to the lung were greatly increased in MMTVneu;miR-22
;MMTV-Cre mice when compared to MMTV-neu control mice of the same age ( Figures 3H and 3I) .
Taken together, these data indicate that miR-22 plays a crucial role in breast stem cell biology, tumorigenesis, and metastasis in vivo. 
miR-22 Triggers MethylationDependent Silencing of miR-200
The E-box-binding transcription factors Zeb1 (also known as TCF8 and dEF1) and Zeb2 (also known as ZFXH1B and SMAD-interacting protein 1 [SIP1]) and the miR-200 family members have been shown to regulate EMT in multiple cancer types (Gregory et al., 2008; Park et al., 2008; Peinado et al., 2007) . Zeb1 and Zeb2 are key transcriptional repressors of E-cadherin, whereas the miR-200 family is known as important regulators of both EMT and mammary stem cell function through direct targeting of the mRNA of both Zeb1/Zeb2 and Bmi1 (Iliopoulos et al., 2010; Shimono et al., 2009) . Strikingly, we found that miR-22 is able to repress miR-200a and miR-200c expression, leading to upregulation of Zeb1, Zeb2, and Bmi1 in both human breast epithelial cells and mouse mammary epithelium prepared from miR-22
;MMTV-Cre mice ( Figures 1B, 4A-4C , and S1E and S1I). Taken together, these data suggest that in mammary epithelial cells miR-22 induces EMT and stemness by suppressing the expression of miR-200 family.
Recent studies have likewise shown that CpG island hypermethylation-mediated epigenetic silencing of the miR-200 family is associated with upregulation of Zeb1/Zeb2 expression, EMT (legend continued on next page) and metastasis (Davalos et al., 2012; Neves et al., 2010; Vrba et al., 2010) . We therefore analyzed the promoter of mir-200 using the methyl-specific PCR (MSP) analysis and found that it is indeed hypermethylated upon miR-22 overexpression (Figure 4D) . Notably, treatment of these cells with a DNA-demethylating agent, 5 0 -aza-2 0 -deoxycytidine (5 0 -Aza), reversed the effects of miR-22 and restored expression of miR-200 transcripts ( Figures 4E and S3A) , suggesting that miR-22 may have a functional role in the dynamic control of DNA methylation.
The recent identification of 5hmC as a novel demethylation standpoint and a biomarker associated with tumor development (Haffner et al., 2011; Nestor et al., 2012; Song et al., 2011; Wu and Zhang, 2010; Yang et al., 2013) prompted us to hypothesize that miR-22 may antagonize miR-200 transcription by controlling 5hmC levels on genomic DNA. Indeed, miR-22 overexpression significantly depleted 5hmC levels within mir-200 promoter CpG islands ( Figure 4F ). Taken together, these results suggest that miR-22 suppresses the demethylation of the promoter within the mir-200 gene and represses its expression, leading to upregulation of its cognate targets.
miR-22
Regulates the Level of 5-Hydroxymethylcytosine by Directly Targeting TET Family Members miR-22 has been shown to exert growth-suppressive functions in vitro in some cancer cell lines (Ling et al., 2012; Pandey and Picard, 2009 ); our investigation, however, revealed an unexpected oncogenic function for miR-22, which we further explored in order to identify the targets of its oncogenic activity in breast cancer. Potential molecular targets of miR-22 were predicted by prediction algorithms including TargetScan 6.0 (http://www.targetscan.org) (Lewis et al., 2005) , microRNA. org (http://www.microrna.org) (Betel et al., 2008) and miRBase (http://www.mirbase.org) (Griffiths- . Among the potential targets, we focused on the TET family-enzymes that contribute to DNA demethylation by converting 5mC to 5hmC and have recently been implicated in epigenetic reprogramming, cellular differentiation and cancer (Ito et al., 2010; Ko et al., 2010; Langemeijer et al., 2009; Tahiliani et al., 2009) (Figures 4G and S3B) . Remarkably, real-time qPCR and western blot analyses revealed that miR-22 expression in MCF-10A and human embryonic kidney (HEK) 293 cells, and in vivo in the mammary glands of miR-22
;MMTV-Cre mice, leads to a robust downregulation of TET family members (Figures 4H and S1I, S3C and S3D) . This was in agreement with the high degree of cross species conservations of the predicted miR-22 micro-RNA recognition elements (MREs) in TET family members ( Figures 4G and S3B) . In contrast, inhibiting miR-22 by using antisense oligonucleotides resulted in a significant elevation in expression of TET family members ( Figure 4I ). Notably, a luciferase reporter assay performed using the 3 0 UTR region of TET2 (which, however, contains the miR-22 MREs also identical within the 3 0 UTR of TET1, TET2, and TET3) ( Figure 4G ), and its mutant version in the miR-22 MREs, demonstrated that miR-22-mediated repression of TET is due to a direct interaction between miR-22 and the TET genes (Figures 4J and S3E and S3F) .
A reduction in the levels of 5hmC has been recently observed in cancer cells, along with inactivation of TET proteins (Haffner et al., 2011; Nestor et al., 2012; Yang et al., 2013) . We therefore next assessed whether miR-22 can remodel the epigenetic landscape by altering 5hmC levels in the genome through the TET family. Dot blot assay and immunofluorescence analysis with anti-5hmC antibodies revealed that miR-22 overexpression is indeed able to reduce global 5hmC levels ( Figures 4K and S3G ). More importantly, 5hmC levels were drastically reduced in vivo in the mammary glands of miR-22
;MMTV-Cre mice compared to littermate controls (Figure 4L) . Taken together, these data suggest that changes in this important epigenetic mark (e.g., 5hmC) may contribute to the ability of miR-22 to impact on EMT, stemness and metastasis.
Downregulation of miR-22 or the TET Family Members Alters EMT, Stemness, and miR-200 Expression Levels
Our observations that ectopic expression of miR-22 promotes EMT and represses TET and miR-200 in turn prompted us to investigate whether miR-22 inhibition could suppress EMT, leading to the elevation of expression of TET and miR-200. To ;MMTV-Cre mice or littermate controls were subjected to real-time qPCR for Tet1, Tet2, and Tet3 mRNA. The data are represented as mean ± SD (n = 3). (I) Total RNAs isolated from MCF-10A cells transfected with the inhibitor (decoy) of miR-22 were subjected to real-time qPCR for TET1, TET2, and TET3 mRNA. The data are represented as mean ± SD (n = 3). (J) Luciferase assay of the luciferase gene linked to the 3 0 UTR of TET2. HEK293 cells were transiently transfected with a combination of pGL3 firefly luciferase reporter plasmids encoding wild-type (left) or mutated (right) 3 0 UTR sequences of human TET2b, miR-22, and a Renilla luciferase reporter for normalization. The data are represented as mean ± SD (n = 3).
(K) Genomic DNA purified from HEK293 cells expressing control miRNA, miR-22, or TET2 siRNA was denatured and neutralized. Global 5hmC levels were then measured by using a dot blot assay with anti-5hmC antibody and normalized by methylene blue staining (left). The resulting 5hmC levels were also quantified (right). The data are represented as mean ± SD (n = 3).
(L) 5hmC-and DAPI-stained sections of the duct of mammary glands isolated from 7-week-old miR-22 (legend continued on next page) address this possibility, we first evaluated miR-22 expression rates in a large panel of breast cancer cells (including two nontumorigenic cells and seven ERa-positive and four ERa-negative breast cancer cell lines); we then focused on LM2 cells as these cells are highly metastatic and express a substantial amount of miR-22 compared to other breast cancer cell lines ( Figure S4A ). Next, we generated a retroviral polymerase II sponge by inserting miR-22-binding sites, arrayed in tandem, into the 3 0 UTR of a reporter gene encoding destabilized GFP driven by the CMV promoter (Figure S4B, top; Ebert et al., 2007) . These miR-22-binding sites were perfectly complementary in the seed region, with a bulge at positions 9-12 to prevent degradation of the sponge RNA ( Figure S4B, bottom) . To examine the effects of miR-22 inhibition on EMT and miR-200 expression, we infected LM2 cells expressing abundant endogenous miR-22 with either the CXCR4 control sponge plasmid (Cont. Sponge) or the sponge plasmid complementary to miR-22 (miR-22 Sponge). Importantly, inhibition of miR-22 by the miR-22 sponge in LM2 cells led to a reduction of metastatic phenotypes, as measured by cell migration, invasion abilities and the expression of the mesenchymal marker vimentin accompanied with elevation in the levels of TET proteins ( Figures 5A and 5B) . Noticeably, inhibiting miR-22 by the miR-22 sponge also resulted in a significant increase in the levels of miR-200 family members ( Figure 5C ). In agreement with these in vitro observations, miR-22 decoying by the miR-22 sponge drastically inhibited in vivo breast cancer metastases to the lung in xenograft models established with LM2 cells (Figures 5D and 5E) .
Next, we investigated whether repression of TET family members could account for the phenotypes caused by miR-22 overexpression in EMT, stemness and metastasis. To this end, we knocked down TET2 or TET3 in MCF-10A cells by using RNA interference (RNAi) and analyzed the resulting effect on EMT and stemness. Notably, knockdown of TET2 or TET3 by RNAi enhanced epithelial cell migration, EMT, and mammosphere formation, suggesting that repression of the TET family creates phenotypes similar to those of miR-22 overexpression (Figures 5F, 5G, 5J, 5K and S4C-S4E). Furthermore, downregulation of TET2 or TET3 resulted in a reduction in 5hmC levels at the mir-200 promoter and caused a decline in miR-200 expression ( Figures 5H, 5I, 5L and 5M) .
To further understand the metastasis-suppression function of TET family members in vivo, we analyzed lung metastases in MCF-7 xenograft models with stable knockdown of TET2. Importantly, mice that received the orthotopic implantation of TET2-depleted MCF-7 cells displayed a suggestive lung metastasis ( Figure S4F ). Taken together, these data indicate that TET family members inhibit EMT, stemness, and tumor metastasis and positively regulate miR-200 expression.
miR-22-Induced EMT, Stemness, and Repression of miR-200 Rely on Its Ability to Silence TET Family Members To finally determine whether TET family members directly contribute to miR-22 function, we ectopically expressed TET2 or TET3 in miR-22-overexpressing MCF-10A cells and then analyzed epithelial cell migration, EMT, and stemness. Importantly, the exogenously expressed TET proteins significantly diminished the cell migration, EMT, and mammosphere formation elicited by miR-22 overexpression ( Figures 6A-6C and 6F-6H). Furthermore, silencing the expression of global 5hmC and miR-200 caused by miR-22 was rescued by the ectopic expression of TET2 or TET3 ( Figures 6D, 6E , 6I, 6J and S4G), suggesting that TET proteins are very likely to be major factors in reliable miR-22 function in suppression of demethylation of miR-200.
To further evaluate whether the invasion-suppression capacity of miR-22 inhibition directly relates to the TET family, we knocked down TET2 or TET3 by RNAi in LM2 metastatic breast cancer cell line after applying the miR-22 sponge ( Figure 6K) . Noticeably, the dramatic reduction in cell invasion caused by miR-22 inhibition was overcome by knockdown of TET proteins ( Figures 6L and S4H) . Taken together, these data suggest that TET family members are the major players responsible for miR-22 function in EMT, stemness and repression of miR-200.
miR-22 Overexpression Correlates with Poor Clinical Outcomes and Silencing of the TET-miR-200 Axis in Patients
Finally, we sought to determine whether our observations could be verified in human breast cancer patients. Indeed, we observed a high expression rate of miR-22 in non-triple-negative breast cancer (non-TNBC) subtypes of breast cancer when compared to normal breast tissue (Figures 7A and S5A and Buffa et al., 2011; Enerly et al., 2011) .
To further evaluate the relationship between miR-22 overexpression and tumor aggressiveness in non-TNBC patients, we analyzed miR-22 levels in breast cancer tissue samples positive for ERa by real-time qPCR, using RNU6B as an internal control. Critically, the breast cancer patients found to have high expression levels of miR-22 had high-grade tumors of an advanced stage (p = 0.047; Figure 7B) , and poor survival rates as compared to the patients with low miR-22 expression levels (p = 0.022, Figure 7C ).
(D and E) H&E-stained sections of primary mammary tumors (left), or H&E-stained and Ki67-stained sections of lungs isolated from mice that received orthotopic injection of control-or miR-22 sponge-infected LM2 cells (right) (D). Scale bars, 100 mm. The incidence of metastases to the lung in mice at 10 weeks after orthotopic injection is also shown (E). (F and J) MCF-10A cells infected with the lentiviral vector expressing TET2 (F) or TET3 (J) shRNA were subjected to the cell migration assay and the migrated cells were then quantified. The data are represented as mean ± SD (n = 3). Interestingly, in this analysis miR-22 was also found to be significantly coexpressed with genes involved in breast cancer metastasis, including those that encode matrix metalloproteases 11 and 1 (Pearson r = 0.536 and 0.392, respectively), cathepsin B (0.500), integrin a11 (0.425), TGF-bR-associated protein (0.416), collagen Xa1 (0.411), TGF-b1 (0.407), fibronectin 1 (0.403), and laminin a5 (0.399) (Bierie and Moses, 2006; McCarthy et al., 1985; Melisi et al., 2008; Radisky and Radisky, 2010; Vuoristo et al., 2007; Withana et al., 2012) (Table S1 ). This observation also supports the notion that in breast cancer miR-22 is prometastatic and contributes to aggressive disease.
More importantly, and consistent with our functional studies, miR-22 expression was directly anticorrelated with the expression of TET1 and TET2 in human breast cancer patients; in addition, a statistically significant anticorrelation between miR-22 and TET3 was also observed but only in the non-TNBC breast cancer subset (Figure 7D and p = 0.014, Figure S5B ). Lastly, we examined whether downregulation of TET family members by miR-22 can explain its effects on miR-200s expression in human breast cancer tissues. In support of this possibility, we found a clear correlation between the expression of TET1 and TET2 and miR-200s in human breast cancer patients; although a correlation was also found between TET3 and miR-200s, this was not statistically significant (Figures 7E and S5C) . Taken together, these results reveal miR-22 as a crucial and unexpected switch for a metastatic phenotype of breast cancer via repression of TET family members/miR-200s.
DISCUSSION
Collectively, our findings have allowed us to reach a number of important conclusions: miR-22 promotes EMT and tumor invasion and metastasis. Using in vivo miR-22 transgenic mouse models, we further show miR-22 can promote lobuloalveolar structures and MSCs stemness and impart mammary tumor development and invasive and metastatic properties. Other studies have demonstrated that miR-22 could play a role in the pathogenesis of breast cancer by interacting with the 3 0 UTR region of ERa and regulating ERa expression (Pandey and Picard, 2009; Xiong et al., 2010) . However, we and others found no effect of miR-22 on expression of ERa in either clinical samples or miR-22
;MMTV-Cre transgenic animals (Figures 1H and S1I and Yoshimoto et al., 2011) .
The findings presented here are coherent with a proto-oncogenic role for miR-22, and with previous findings implicating miR-22 in the regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor (Poliseno et al., 2010) . Although inactivation of PTEN may contribute See Figure S5 and Table S1 .
to the role of miR-22 in breast cancer initiation, it has little effect on EMT in the various tissues including breast (S.J.S. and P.P.P., unpublished data and Mulholland et al., 2012; Shorning et al., 2011; Wang et al., 2012) . Moreover, unlike miR-22
;MMTV-Cre transgenic mice, the 5hmC levels in precancerous mammary glands of Pten mutant mice were not appreciably different from littermate controls, indicating that miR-22 functions as an epigenetic modifier and EMT promoter independently of its ability to target PTEN ( Figure S3H ).
We propose a mechanism and a model for antagonistic miRNA crosstalks whereby one miRNA (e.g., miR-22) can suppress the expression of another miRNA (e.g., miR-200) via direct targeting of chromatin remodeling enzymes such as TET family members, which in this specific example in turn leads to the hypermethylation of the mir-200 promoter and induction of EMT and stemness ( Figure 7F ). Indeed, aberrant DNA methylation of CpG islands from mir-200 family appears to be closely linked to their silencing during EMT and metastasis, whereas epigenetic modifier drugs such as 5-aza-2 0 -deoxycytidine can reactivate miR-200 family expression, indicating that epigenetic mechanisms play a functional role for controlling the expression of this family in cancer (Davalos et al., 2012; Li et al., 2010; Vrba et al., 2010) . TET2-inactivating deletion and mutations have been observed in hematopoietic malignancies (Shih et al., 2012) , and yet to date, whether TET family members play a role in solid tumors and metastasis remained an open question. Our results, i.e., that inhibition of TET proteins triggers a similar phenotype as miR-22 overexpression in EMT and stemness and that the phenotypes caused by miR-22 are abolished by ectopic expression of TET proteins, demonstrate that the TET family acts as a major target in mediating the function of miR-22 in breast cancer and metastasis. In turn, these data suggest that the functional and concomitant loss of TET family members may be extremely relevant to the pathogenesis of solid tumors.
It has also been recently reported that mutations of the isocitrate dehydrogenase genes IDH1 and IDH2 can lead to the aberrant production of 2-hydroxyglutarate (2-HG), a metabolite that inhibits TET2 enzymatic activity, resulting in a hypermethylated promoter phenotype in acute myeloid leukemia (AML) tumors carrying IDH1/2 mutations (Figueroa et al., 2010) , further highlighting a possible critical role for TET family members in the epigenetic deregulation observed in many cancers. Importantly, beside mutations specifically targeting TET2 or IDH1/2 genes, our results now reveal an additional and global silencing mechanism of the whole TET family by miR-22, which can block the 5mC-to-5hmC conversion and thus DNA demethylation. The fact that miR-22 can target multiple TET family members at once explains on the one hand its powerful effects on the global epigenetic landscape but also its potent proto-oncogenic role in multiple tissues (Song et al., 2013) .
Our findings not only help at further defining the molecular basis of tumor metastasis, but also have important implications for the diagnosis, prognosis and treatment of cancer. As miR-22 triggers EMT and a metastatic phenotype and its overexpression correlates with poor clinical outcomes in patients, it might be utilized as a useful biomarker to identify metastatic forms of breast cancer. Critically, our results that inhibiting miR-22 by the miR-22 sponge in highly metastatic cells leads to a reduction of metastatic phenotypes, as well as an elevation of the expression of TET and miR-200, provide a rationale for the therapeutic targeting of miR-22 (e.g., by using the LNA [locked nucleic acid] miR-22 inhibitors) in order to prevent EMT and metastatic phenotypes.
EXPERIMENTAL PROCEDURES Mice
Cre-inducible miR-22 expression construct was generated in which a LoxPflanked transcriptional STOP element was inserted between a CAGGS promoter and mir-22. This construct was targeted into the mouse Collagen A1 locus using Flp recombinase-mediated genomic integration. Mouse embryonic stem cells carrying a single copy of the mir-22 STOP construct were identified by resistance to the antibiotic marker hygromycin and Southern blotting. Selected clones were injected into blastocysts to generate pups. 
Immunohistochemistry
Tissues were fixed in 4% Paraformaldehyde and wash with PBS and transfer to 70% ethanol and then embedded in paraffin in accordance with standard procedures. Sections were stained for hematoxylin and eosin (H&E), Ki-67 (Novocastra), GFP (Cell Signaling), MECA-32 (BioLegend), ERa (Abcam), TTF1 (DAKO), Cytokeratin-8 (Abcam), and cytokeratin-14 (Novus Biologicals). 5-hydroxymethylcytosine-specific antibody (Active Motif) was applied at 1:1,000 dilutions for tissue immunofluorescence analysis.
Orthotopic Injection
Four-week-old female Nu/Nu immunodeficient mice (Jackson Laboratory) were used for surgery. Mice were anaesthetized with isoflurane. The skin was incised and the endogenous mammary epithelial was removed from the 4 th fat pad from the nipple connect to the part distal of the mammary lymph node by electrocauterization before the implantation. Then, MCF-7 or LM2 cells (1 3 10 5 ) in 50 ml growth medium/matrigel (BD Biosciences) were injected into the rest of mammary fat pad (n = 6). For an E2 supplementation, mice have been given injections of b-estradiol (Sigma) dissolved in pure sesame oil (0.1 mg per 0.05 ml sesame oil per mouse, subcutaneously) 1 day before orthotopic injection of MCF-7 cells, and then at weekly intervals until the conclusion of the experiment.
Whole-Mount Staining
The fourth inguinal glands were dissected at the indicated ages and were spread on a glass slide. After fixation with acidic alcohol for 2 hr, the tissues were hydrated and stained in Carmine alum for overnight as described (Jackson-Fisher et al., 2004) . Samples were then dehydrated, cleared with xylene, and mounted.
Mouse Mammary Stem Cell Analysis
Mammary glands were dissected from 7-week-old female mice. After mechanical dissociation, the cells were prepared and analyzed. All reagents were from StemCell Technologies. Cells were stained with biotinylated anti-CD45, -Ter119, -CD31, and -CD140a (eBioscience) for 1 hr on ice. After extensive washing with PBS/2%FBS, cells were stained with anti-CD24-FITC, -CD29-PE, -CD49f and streptavidin-APC-eBluor 780 (eBioscience) for 45 min on ice. For a flow cytometric analysis, DAPI-negative cells were gated and analyzed. Mammary stem cell transplantation assay was performed as previously described (Shimono et al., 2009 ).
Human Patient Samples
Human patient samples were analyzed as described in detail in the Extended Experimental Procedures. This study was approved by the institutional review boards of Dana Farber/Harvard Cancer Center.
Glucosylation of Genomic 5hmC Followed by Methylation-Sensitive qPCR Genomic DNA was treated with T4 Phage b-glucosyltransferase (T4-BGT, New England Biolabs) according to the manufacturer's instruction. Glucosylated genomic DNA (100 ng) was digested with 10 U of HpaII, MspI or no enzyme (mock digestion) at 37 C overnight, followed by inactivation for 20 min at 80 C. The HpaII-or MspI-resistant fraction was quantified by qPCR using primers designed around at least one HpaII/MspI site, and normalizing to the mock digestion control. Resistance to MspI directly translates into percentage of 5hmC, whereas 5mC levels were obtained by subtracting the 5hmC contribution from the total HpaII resistance.
Methylation-Specific PCR DNA methylation status was examined by the methylation-specific PCR with genomic DNA treated with sodium bisulfite using the EZ DNA MethylationDirect kit (Zymo Research). Primers as described were used (Davalos et al., 2012) .
Statistical Analysis
Student's t test was utilized to determine statistical significance unless otherwise specified. p values lower than 0.05 were considered statistically significant. The details of plasmids, cell culture and transfection, immunocytochemistry, real-time quantitative PCR, luciferase reporter assay, dot and western blot analyses and cell migration and invasion assay are also described in the Extended Experimental Procedures. 
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